Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05536453
Other study ID # CP-000003
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date August 16, 2022
Est. completion date August 16, 2025

Study information

Verified date November 2023
Source Spine and Scoliosis Research Associates
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The objective of this retrospective study is an investigational clinical follow-up, of patients treated with interbody fusion devices (IBFD), both expandable (EXP) and static (STC), according to their intended use and cleared labeling to understand IBFD design and technique characteristics that affect occurrence rates of subsidence. Patients treated with IBFD's (both EXP and STC) according to their intended use and cleared labeling 1. EXP IBFD's that expand in width and height demonstrate reduced occurrence of subsidence post-operatively when compared to EXP IBFD's that expand in height only and STC IBFD's. 2. EXP IBFD's that are comprised of multi-material composition with Polyetheretherketone (PEEK) endplate contacting surfaces demonstrate reduced occurrence of subsidence on post-operative radiographs when compared to EXP and STC IBFD's that are primarily comprised of Ti with Ti endplate contacting surfaces. 3. achieve radiographic fusion at a rate consistent with the state-of-the-art 4. achieve significant improvements in pain and function compared to baseline 5. experience adverse events at a frequency comparable to reported rates for TLIF or PLIF surgery 6. not demonstrate any intraoperative complications during the implant process 7. operative approach does not correlate with increased rates of subsidence


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 5000
Est. completion date August 16, 2025
Est. primary completion date August 16, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 110 Years
Eligibility Inclusion Criteria: 1. The patient was treated with TLIF or PLIF surgery using the IBFD according to the cleared labeling, based on the surgeon's clinical judgment and patient-specific decision making. Based on the product labeling, the patient must: 1. Was at least 18 years of age and skeletally mature at the time of surgery 2. Had clinical and radiological evidence of DDD of the lumbar spine 3. Undergone treatment with the IBFD with autogenous bone graft and/or allogeneic bone graft composed of cancellous and/or corticocancellous bone at 1 or 2 contiguous levels from L2 to S1 Exclusion Criteria: 1. History of fusion surgery or large laminectomy at L2 to S1 prior to treatment with the IBFD(s) Spondylolisthesis unable to be reduced to grade 1 as part of the surgical procedure 2. Surgery with the IBFD(s) at more than 2 contiguous levels 3. Surgery with the IBFD(s) at levels outside the range of L2 to S1 4. Treated with any bone grafting material other than autogenous or allogenic bone graft in the device(s) or surrounding disc space 5. Any contraindications listed in the cleared product labeling 6. Osteoporosis, Other Systemic Bone D.O. T score = -1.5 7. BMI > 40 8. Systemic Infection 9. H/O IV Drug Use 10. Cancer

Study Design


Intervention

Device:
Lumbar Interbody Fusion Devices
Posterior Lumbar Interbody Fusion device placed to treat symptoms associated with degenerative disc disease

Locations

Country Name City State
United States Rothman Orthopaedic Institute Bensalem Pennsylvania
United States Carolina NeuroSurgery & Spine Associates Charlotte North Carolina
United States New York University Langone Health New York New York
United States University of California San Francisco San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
Spine and Scoliosis Research Associates

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Subsidence Radiographic subsidence immediately postoperatively (first erect), at 12 months, and at 24 months as evaluated by an independent reviewer. Where subsidence is defined as = 2mm cage penetration of the cephalad, caudal end plate, or both.
Intraoperative subsidence will be classified when fluoroscopic images identify end plate violation, and postoperative subsidence is classified by the absence of violation on intraoperative fluoroscopy, but present on 12-month lateral radiographs and/or 24 months.
24 months
Secondary Incidence of Fusion Radiographic fusion at 12 months and at 24 months follow-up, as evaluated by up to 3 independent reviewers (2 primary reviewers and 1 adjudicator, as needed for disagreements).
Fusion status will be determined according to the Bridwell-Lenke grading system (Bridwell et al. 1995), with grades 1-2 accepted as "Fused" and grades 3-4 accepted as "Not Fused."
For subjects determined to be fused at 12 months, additional X-rays will not be required at 24 months unless the treating surgeon determines that radiographs are otherwise needed for the patient. The last-observation-carried-forward (LOCF) approach will be employed for 24-month fusion assessments where additional radiographs were not collected beyond 12 months.
24 months
Secondary Incidence of End Plate Violation Incidence of end plate violation determined based upon operative reports and medical records. 12 months
Secondary Visual Analog Scale (VAS) Scores for Leg Pain, if available Comparison of VAS scores for leg pain between baseline and 12 months post-operatively and baseline and 24 months post-operatively. The scores range from 0 to 100, with higher numbers indicating more pain. 24 months
Secondary VAS Scores for Back Pain, if available Comparison of VAS scores for back pain between baseline and 12 months post-operatively and baseline and 24 months post-operatively. The scores range from 0 to 100, with higher numbers indicating more pain. 24 months
Secondary Oswestry Disability Index (ODI) Scores, if available Comparison of ODI scores between baseline and 12 months post-operatively and baseline and 24 months post-operatively. The scores range from 0 to 100, with higher numbers indicating more disability. 24 months
Secondary Incidence of Device and/or Procedure-Related Adverse Events Incidence of device and/or procedure-related adverse events determined based upon operative reports and medical records. 24 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00775801 - Freedom Lumbar Disc in the Treatment of Lumbar Degenerative Disc Disease N/A
Enrolling by invitation NCT02171169 - Retrospective, Multicenter Clinical Evaluation of Health Economic Drivers and Complications for Two Lumbar Fusion Procedures N/A
Not yet recruiting NCT06011551 - HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs N/A
Terminated NCT00374413 - Kineflex|C Artificial Disc System to Treat Cervical Degenerative Disc Disease (DDD) N/A
Active, not recruiting NCT01551901 - Luna Interbody System for Fusion Trial N/A
Recruiting NCT05489822 - PMCF Study to Evaluate the VERTICALE® Cervical System in Spine Surgery According to Its Intended Use.
Active, not recruiting NCT03737461 - Efficacy of Intradiscal Injection of BM-MSC in Subjects With Chronic Low Back Pain (LBP) Due to Lumbar Degenerative Disc Disease (DDD) Unresponsive Phase 2/Phase 3
Completed NCT01972256 - A Study Comparing Fusion Rates of Two Lumbar Fusion Procedures N/A